This NDA submission is an important milestone, and it brings gedatolisib one step closer to becoming available for patients with HR+/HER2- advanced breast cancer,” said Brian Sullivan, CEO and ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...

FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) ...

São Paulo imitated the defense used by Vitor Roque, a forward for Palmeiras, in an attempt to reach an agreement with the ...

São Paulo imitated the defense used by Vitor Roque, a forward from Palmeiras, in an attempt to reach an agreement with the ...

Q3 2025 Earnings Call Transcript November 12, 2025 PolyPid Ltd. beats earnings expectations. Reported EPS is $-0.37, ...

A round-up of news from around the region, including Nauru's deputy minister for public health saying diabetes is a national ...

Q3 2025 Earnings Call Transcript November 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Research and development (R&D) expenses for the three months ended September 30, 2025, were $5.3 million, compared to $6.0 million in the same three-month period of 2024 and a decrease from $6.2 ...

ADJUDICATOR’S JURISDICTION TO ORDER PAYMENT OF AN INTERIM APPLICATION NOTIFIED SUM WITHIN A TRUE VALUE ADJUDICATION- The ...

Q3 2025 Earnings Call November 17, 2025 8:30 AM ESTCompany ParticipantsMatthew Duffy - Chief Business Officer & ...

Given that the Gas have lost their last six games, we have decided to look at six problems facing the club ahead of the trip ...